BioTime (BTX) Trading Up 8.9%
BioTime, Inc. (NYSEAMERICAN:BTX) shares were up 8.9% during trading on Thursday . The company traded as high as $2.20 and last traded at $2.09. Approximately 591,516 shares changed hands during mid-day trading, an increase of 25% from the average daily volume of 474,338 shares. The stock had previously closed at $1.92.
Separately, Zacks Investment Research downgraded BioTime from a “buy” rating to a “hold” rating in a report on Tuesday, July 24th.
BioTime (NYSEAMERICAN:BTX) last released its earnings results on Thursday, August 2nd. The biotechnology company reported ($0.06) EPS for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.03. BioTime had a return on equity of 30.68% and a net margin of 828.55%. The company had revenue of $2.55 million for the quarter, compared to the consensus estimate of $0.33 million.
BioTime Company Profile (NYSEAMERICAN:BTX)
BioTime, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing products addressing degenerative diseases based on pluripotent stem cells and HyStem cell/drug delivery platform technologies primarily in the United States and Israel. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; and Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV-associated facial lipoatrophy.
Featured Story: What is the NASDAQ Stock Market?
Receive News & Ratings for BioTime Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTime and related companies with MarketBeat.com's FREE daily email newsletter.